The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
 
Tanya B. Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Exelixis; Janssen Oncology; Pfizer; Sanofi/Aventis; Seagen
Research Funding - Pfizer (Inst)
 
Suzette Blanchard
Research Funding - MustangBio
 
Hripsime Martirosyan
No Relationships to Disclose
 
Lauren Adkins
No Relationships to Disclose
 
Gaurav Dhapola
No Relationships to Disclose
 
Stephanie Shishido
No Relationships to Disclose
 
Jamie R Wagner
No Relationships to Disclose
 
Tracey Stiller
No Relationships to Disclose
 
Massimo D'Apuzzo
No Relationships to Disclose
 
Peter Kuhn
Stock and Other Ownership Interests - Cansera; Earli; Epic Sciences; forbie; Sampling Human
Consulting or Advisory Role - Epic Sciences
Research Funding - Abbvie; Amgen; Daiichi Sankyo; Fluidigm; Gilead Sciences; Kite, a Gilead company; Lilly; Novartis
Patents, Royalties, Other Intellectual Property - HDSCA liquid biopsy technology developed in the Kuhn laboratory initially at The Scripps Research Institute and subsequently at the University of Southern California and related patents have been licensed for commercial development to Epic Sciences.; Patent 62/783,921: "System and Method for Determining Human Performance". Systems and methods in human performance to determine whether a cancer patient will need unplanned medical care during cancer therapy.
 
Stephen J. Forman
Stock and Other Ownership Interests - MustangBio
Consulting or Advisory Role - Alimera Sciences; Lixte Biotechnology; MustangBio
Research Funding - MustangBio
 
Saul Priceman
Stock and Other Ownership Interests - Adicet Bio; Imugene
Consulting or Advisory Role - Adicet Bio; Bayer; Imugene; MustangBio
Research Funding - Carisma Therapeutics; Imugene
Patents, Royalties, Other Intellectual Property - CAR Therapeutic; Oncolytic Virus Therapeutic